Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2024 | Outperform → Market Perform | TD Cowen | |
| 2/27/2024 | Buy → Neutral | Citigroup | |
| 5/3/2023 | $6.00 | Buy | Citigroup |
| 10/18/2022 | $29.00 → $4.00 | Buy → Neutral | Goldman |
| 10/18/2022 | $42.00 → $4.00 | Strong Buy → Outperform | Raymond James |
| 10/17/2022 | Buy → Hold | Jefferies | |
| 10/17/2022 | Overweight → Neutral | Piper Sandler |
15-12G - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
EFFECT - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)
25-NSE - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)
Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab)Announced the appointment of Dan Kaplan, Ph.D. to Chief Scientific OfficerExtended expected cash runway into the second quarter of 2025 following a restructuring o
INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model. Ms. Obi Felton, Ms. Siobhan Nolan Mangini, Dr. Glenn Steele and Mr. Bill Whitely bring a strong and diverse set of track records and experience, spanning leadership in clinical quality, patient experience, technology, and rapid growth. Marathon's appointment of these four Directors comes at an exciting inflecti
Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumorsAmended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope$390.6 million in cash, cash equivalents and marketable securities as of June 30, 2021 SOUTH SAN
Raymond James analyst Steven Seedhouse downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Market Perform.
NGM Biopharmaceuticals (NASDAQ:NGM) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 26.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $165.00 thousand which missed the analyst consensus estimate of $560.00 thousand by 70.54 percent. This is a 99.09 percent decrease over sales of $18.18 million the same period last year.
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. ("Parent"), an affiliate of The Column Group, LP ("TCG"), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. ("Merger Sub"), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain other stockholders at a price per share of $1.55 in cash (the "Offer Price"). The tender offer and related withdrawal rights expired at one minute a
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose esca
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024-- --Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing chola
Raymond James downgraded NGM Biopharmaceuticals from Outperform to Mkt Perform
TD Cowen downgraded NGM Biopharmaceuticals from Outperform to Market Perform
Citigroup downgraded NGM Biopharmaceuticals from Buy to Neutral
Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEsAdditional analyses to be presented in early November at The Retina Society Annual Scientific MeetingNGM Bio to host conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. To access the live webcast and slides, please visit the "Investors & Media" section of NGM Bio's website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. About NGM Bio NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives ha